Navigation Links
NORD Sponsors Rare Disease Summit
Date:5/14/2009

WASHINGTON, May 14 /PRNewswire-USNewswire/ -- A shortage of new pharmaceutical products in the pipeline combined with new scientific tools has created a climate of opportunity for the rare disease community, a senior Food and Drug Administration (FDA) official said today at a conference hosted by the National Organization for Rare Disorders (NORD).

The blockbuster model is no longer viable, said Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at FDA. As a result, she said, companies are more willing to consider new options, including more products for rare diseases.

Former National Human Genome Research Institute Director Francis Collins, MD, PhD, agreed, adding that it's time to de-risk orphan drug development, making it a more viable business model for companies.

Collins and Woodcock were among several speakers at a Partners in Progress Summit hosted by NORD in Washington, DC. NORD represents the nearly 30 million Americans who have rare diseases, or ones affecting fewer than 200,000 people.

Peter L. Saltonstall, NORD's president and CEO, noted that most rare diseases have no FDA-approved treatment and many patients are denied insurance for unapproved treatments. NORD sponsored the summit, he said, to develop a policy agenda for action to spur development of new therapies and ensure that patients have access to them.

Former FDA Commissioner David Kessler, MD, moderated the event. Speakers included thought leaders in government and industry working with rare diseases and orphan products. A theme articulated by several speakers was that now is the time for rare disease patients and researchers to press their case.

The healthcare system we know today is going to be completely transformed over the next 12 months, said Tommy Thompson, former governor of Wisconsin and former Secretary of Health and Human Services. Now is the time for action.

NORD Board of Directors Vice Chairman Frank Sasinowski announced the formation of a Rare Disease Congressional Caucus to seek creative solutions to problems faced by patients and to serve as a forum for discussion of issues related to access, research, and increased innovation.

The Caucus will also seek to increase funding for two government agencies the National Institutes of Health Office of Rare Diseases Research and the FDA Office of Orphan Products Development. In addition, it will address regulatory issues facing the pharmaceutical, biotechnology, and medical device industries, Sasinowski said.

Social Security Commissioner Michael Astrue described efforts to expedite the process of applying for Social Security disability assistance for people with severely disabling rare diseases. Under Commissioner Astrue, the Social Security Administration last fall launched a new Compassionate Allowances initiative to reduce problems encountered by people with certain severe diseases when they apply for assistance.

Presentations from the Partners in Progress Summit will be posted soon on the NORD website at www.rarediseases.org.


'/>"/>
SOURCE National Organization for Rare Disorders (NORD)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York
2. HealthCentral.com Collaborates With BreastCancer.org, Providing Quality Awareness Sponsorships to #1 Breast Cancer Resource Online
3. Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act 2009 Increases to 27 Members
4. Celebrate the Beauty of Motherhood - American Laser Centers Sponsors RoleMommy.com Mothers Day Spa Retreat & Style Lounge
5. Cosmetic Bootcamp Announces Sold Out Sponsorship for Upcoming Meeting
6. Turtle Island Oxygen Trust Sponsors Free Hyperbaric Treatments
7. Cardinal Rigali Praises House Re-Introduction of Pregnant Women Support Act, Urges Co-Sponsorship
8. Prime Sponsors at 2009 American Heart Walk
9. Paying it Forward: Washington, DC LASIK Vision Care Practice Sponsors New Contest to Reward Good Deeds
10. American Laser Centers Sponsors SELF Magazines Workout in the Park
11. Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
Breaking Medicine Technology: